Cogent Biosciences (COGT) Operating Expenses (2017 - 2026)

Cogent Biosciences' Operating Expenses history runs 10 years deep, the most recent figure standing at $103.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 38.27% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $362.0 million (up 25.5% YoY), while the FY2025 annual figure was $333.4 million, up 20.81% from the prior year.
• Operating Expenses was $103.6 million for Q1 2026 at Cogent Biosciences, up from $99.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $103.6 million in Q1 2026 to a low of $31.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $62.9 million across 5 years, with a median of $62.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 145.45% in 2022, then increased 10.53% in 2025.
• A 5-year view of Operating Expenses shows it stood at $43.7 million in 2022, then jumped by 33.11% to $58.2 million in 2023, then gained by 26.63% to $73.7 million in 2024, then soared by 34.94% to $99.5 million in 2025, then grew by 4.13% to $103.6 million in 2026.
• The last three Operating Expenses figures came in at $103.6 million (Q1 2026), $99.5 million (Q4 2025), and $83.4 million (Q3 2025), per Business Quant data.